ReviewImmune network2025
VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies.
Review in Immune network, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications.Medical oncology (Northwood, London, England) · 2026Review
- Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review).Oncology letters · 2026Review
- Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies.Immune network · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) offer tremendous promise as therapeutic targets for a range of tumor types, and their development is advancing rapidly in cancer treatment. Nevertheless, the limited efficacy of anti-PD-1/PD-L1 immunotherapy in several cancers has driven researchers to explore other immune checkpoints as potential therapeutic targets. The inhibitory V-domain Ig suppressor of T-cell activation (VISTA) appears to be a captivating candidate. As a member of the B7 family, VISTA is expressed on hematopoietic cells and has the ability to significantly suppress T cell function and the anti-tumor immune response. In this review, our objective is to shed light on the multifaceted potential of VISTA as a therapeutic target. We will highlight the expressions and role of VISTA in various cancer types. Subsequently, we will go through distinct potential VISTA ligands, while underscoring the role of the pathway within the tumor microenvironments (TME). Finally, we will conclude with a comprehensive overview of the latest clinical trials, highlighting VISTA's emerging potential in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.